Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lytic Cycle of Bacteriophages01:30

Lytic Cycle of Bacteriophages

Bacteriophages, also known as phages, are specialized viruses that infect bacteria. A key characteristic of phages is their distinctive “head-tail” morphology. A phage begins the infection process (i.e., lytic cycle) by attaching to the outside of a bacterial cell. Attachment is accomplished via proteins in the phage tail that bind to specific receptor proteins on the outer surface of the bacterium. The tail injects the phage’s DNA genome into the bacterial cytoplasm. In the lytic replication...
DNA Bacteriophages01:26

DNA Bacteriophages

Bacteriophages, or phages, are viruses that specifically infect bacteria, utilizing their genetic material to hijack host cellular machinery for replication. DNA bacteriophages employ single-stranded DNA (ssDNA) or double-stranded DNA (dsDNA) genomes. These phages exhibit diverse replication strategies and host interactions, influencing their ecological roles and applications in biotechnology and medicine.ssDNA BacteriophagesssDNA phages, with their small genomes, utilize unique strategies to...
Lysogenic Cycle of Bacteriophages00:43

Lysogenic Cycle of Bacteriophages

In contrast to the lytic cycle, phages infecting bacteria via the lysogenic cycle do not immediately kill their host cell. Instead, they combine their genome with the host genome, allowing the bacteria to replicate the phage DNA along with the bacterial genome. The incorporated copy of the phage genome is called the prophage. Some prophages can re-activate and enter the lytic cycle. This often occurs in response to a perturbation, such as DNA damage, but can also transpire in the absence of...
Bacteriophages of the Human Virome01:23

Bacteriophages of the Human Virome

Bacteriophages are found throughout the human body. They may even outnumber eukaryotic viruses, forming an important and dynamic component of the human virome. Indeed, phages represent the most abundant viral entities, with densities in the gut reaching up to 10⁹ particles per gram of fecal matter, and many belonging to orders such as Caudovirales and Microviridae, while a substantial proportion remains unclassified as viral “dark matter.”Lysogeny and Genetic ExchangeIn the gut, bacteriophages...
Viral Replication: Lysogenic Cycle01:16

Viral Replication: Lysogenic Cycle

The lysogenic cycle is a crucial viral replication strategy that allows bacteriophages to persist within host cells without immediately destroying them. This process is primarily observed in temperate phages, such as bacteriophage lambda (λ), which infects Escherichia coli. The cycle allows the viral genome to persist across bacterial generations while keeping host cells viable.Integration of the Viral GenomeUpon infection, bacteriophage lambda attaches to the bacterial surface and injects its...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A guide to the ecological limitations of phage therapy of bacterial biofilms: Is what's best for the phage best for the physician?

The FEBS journal·2026
Same author

From hype to hope: reanimating phage therapy through evidence-based multidisciplinarity.

Nature communications·2026
Same author

Bacteriophage titering by optical density means: KOTE assays.

Open life sciences·2026
Same author

Broth Optical Density-Based Assessment for Phage Therapy: Turbidity Reduction, Antibacterial Virulence, and Time-Kill.

Viruses·2026
Same author

Optical Density-Based Methods in Phage Biology: Titering, Lysis Timing, Host Range, and Phage-Resistance Evolution.

Viruses·2025
Same author

Dual-Receptor Recognition, Lysis Inhibition, Endolysin Release, and Reaction-Diffusion as Alternative Explanations. Comment on Rojero et al. Bypassing Evolution of Bacterial Resistance to Phages: The Example of Hyper-Aggressive Phage 0524phi7-1. <i>Int. J. Mol. Sci.</i> 2025, <i>26</i>, 2914.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Jun 15, 2026

Understanding the Impact of Temperate Bacteriophages on Their Lysogens Through Transcriptomics
09:23

Understanding the Impact of Temperate Bacteriophages on Their Lysogens Through Transcriptomics

Published on: January 5, 2024

Phage therapy pharmacology.

Stephen T Abedon1, Cameron Thomas-Abedon

  • 1Department of Microbiology, The Ohio State University, 1680 University Dr., Mansfield, OH 44906, USA. abedon.1@osu.edu

Current Pharmaceutical Biotechnology
|March 11, 2010
PubMed
Summary

Phage therapy uses bacteria-specific viruses for treatment. Understanding phage pharmacokinetics and pharmacodynamics is key to improving its safety and efficacy compared to antibiotics.

Area of Science:

  • Bacteriology
  • Virology
  • Pharmacology

Background:

  • Phage therapy utilizes bacteriophages (viruses that infect bacteria) to combat bacterial infections.
  • The process involves phage penetration and bacterial killing, with ecological interactions between phages, bacteria, and host tissues.
  • Viewing phages as antibacterial agents necessitates a pharmacological framework, encompassing pharmacokinetics and pharmacodynamics.

Purpose of the Study:

  • To explore the application of pharmacokinetic and pharmacodynamic principles to phage therapy.
  • To identify strategies for rationally improving phage therapy efficacy and safety.
  • To compare the advantages of phage therapy over traditional antibiotic treatments.

Main Methods:

  • Conceptual analysis framing phage-environment interactions within a pharmacological context.

More Related Videos

Bacteriophage Effectiveness for Biocontrol of Foodborne Pathogens Evaluated via High-Throughput Settings
07:22

Bacteriophage Effectiveness for Biocontrol of Foodborne Pathogens Evaluated via High-Throughput Settings

Published on: August 19, 2021

T4 Bacteriophage and E. coli Interaction in the Murine Intestine: A Prototypical Model for Studying Host-Bacteriophage Dynamics In Vivo
08:46

T4 Bacteriophage and E. coli Interaction in the Murine Intestine: A Prototypical Model for Studying Host-Bacteriophage Dynamics In Vivo

Published on: January 26, 2024

Related Experiment Videos

Last Updated: Jun 15, 2026

Understanding the Impact of Temperate Bacteriophages on Their Lysogens Through Transcriptomics
09:23

Understanding the Impact of Temperate Bacteriophages on Their Lysogens Through Transcriptomics

Published on: January 5, 2024

Bacteriophage Effectiveness for Biocontrol of Foodborne Pathogens Evaluated via High-Throughput Settings
07:22

Bacteriophage Effectiveness for Biocontrol of Foodborne Pathogens Evaluated via High-Throughput Settings

Published on: August 19, 2021

T4 Bacteriophage and E. coli Interaction in the Murine Intestine: A Prototypical Model for Studying Host-Bacteriophage Dynamics In Vivo
08:46

T4 Bacteriophage and E. coli Interaction in the Murine Intestine: A Prototypical Model for Studying Host-Bacteriophage Dynamics In Vivo

Published on: January 26, 2024

  • Distinguishing between pharmacokinetics (body's effect on phage) and pharmacodynamics (phage's effect on bacteria and body).
  • Evaluating the role of phage replication in achieving therapeutic outcomes.

    • Main Results:

    • Phages offer advantages over antibiotics in terms of safety and ease of discovery.
    • Effective phage therapy requires achieving high phage "killing titers".
    • Relying solely on in situ phage replication for sufficient titers may be unreliable.

    Conclusions:

    • A deeper understanding of phage pharmacokinetics and pharmacodynamics can optimize phage therapy.
    • Phage replication can contribute to a "margin of safety" for therapeutic efficacy.
    • Phage therapy presents a promising alternative or adjunct to antibiotics, contingent on achieving adequate phage concentrations.